C
엑세스바이오
950130KOSDAQ46.0 / 100
Reference Date: 2026-09-08
Financial Score15.5 / 40
News Sentiment12.5 / 25
Momentum8.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Rose 6.7% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
AccessBio develops and sells diagnostic products based on in-vitro diagnostics (IVD) technologies, focusing on infectious disease rapid diagnostic tests (RDTs) for malaria, influenza, and COVID-19. Its COVID-19 diagnostic products, which received FDA Emergency Use Authorization, have become a major revenue driver, with the company expanding globally amid growing IVD market demand.
Number of Employees
75people
Average Salary
159.0M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
—Industry Average 1.203.5Point
ROE
-14.02Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
4.40Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 2023~20250.0 / 10 points
Revenue Growth Rate
0.0 / 3
Avg ▼71.2% (2-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼727.6% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -5.0% (declining, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (14%, downtrend)
Current 2,455Won52-week high 5,03052-week low 2,020
1-month return4.0Point
1m +6.74% (slight rise)
Volume trend3.0Point
Volume flat
Detailed Disclosure
1 totalPositive 0Neutral 1Negative 0
- Neutral반기보고서 (2026.06)2026-08-14